Cerebrospinal Fluid and Plasma Lopinavir Concentrations and Viral Response in Virologically Suppressed Patients Switching to Lopinavir/Ritonavir Monotherapy Once Daily
Free accessAnnouncementFirst published online May, 2016
Cerebrospinal Fluid and Plasma Lopinavir Concentrations and Viral Response in Virologically Suppressed Patients Switching to Lopinavir/Ritonavir Monotherapy Once Daily
Lopinavir/ritonavir (LPV/r) monotherapy is used in selected virologically suppressed HIV-infected patients. Some would prefer a once-daily (OD) dose instead of the usual twice-daily dose to favour adherence. However, trough concentrations of the drug in blood and particularly in cerebrospinal fluid (CSF) may not be adequate to maintain viral suppression.
Methods
Prospective, open-label pilot study to evaluate the efficacy and safety of LPV/r monotherapy OD. HIV-1-infected patients, virologically suppressed for at least 6 months were enrolled. HIV viral load (VL) was determined at baseline and at weeks 4, 8, 12, 16, 24, 36 and 48. Lumbar puncture was performed in a subgroup of patients to evaluate CSF VL and CSF LPV concentrations.
Results
A total of 21 patients were included. At week 48, 85.7% (n=18) showed viral suppression (VL<40 copies/ml). Two patients had viral failure (9.5%) and a third was withdrawn from the study because of gastrointestinal symptoms. Nine patients were enrolled in the substudy. CSF VL was <40 copies/ml in all cases. Median (range) LPV concentration was 9.78 ng/ml (1.93–78.3) in CSF and 1,970 (154–16,700) ng/ml in plasma; the CSF/plasma ratio was 0.004 (0.001–0.186).
Conclusions
In this small pilot study, LPV/r monotherapy OD maintained plasma HIV RNA suppression at 48 weeks in most patients, with no cases of CSF viral escape. However, CSF LPV concentrations were close to the 50% inhibitory concentration threshold in several patients; hence, this intervention should be avoided in patients with advanced immune suppression and/or those individuals presenting with significant comorbidities such as hepatitis C coinfection.
References
1.
ArribasJ., GirardP.M., PatonN.Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials.J Int AIDS Soc2014; 17: 19788.
2.
GatellJ.M., ArribasJ.R., GirardP.M.Non-inferiority of dual-therapy (DT) with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) vs. triple-therapy (TT) with LPV/r plus two nucleos(t)ides (NRTIs) for maintenance of HIV viral suppression: 48-week results of OLE study.20th International AIDS Conference. 20–25 July 2014, Melbourne, Australia. Abstract LBPE17.
3.
BurgosJ., CrespoM., FalcóV.Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.J Antimicrob Chemother2012; 67: 2479–2486.
Expert Panel of GeSIDA and the National Aids Plan, Berenguer J, Polo R, et al.Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).Enferm Infecc Microbiol Clin201432: 447–458.
6.
ParientiJ.J., BangsbergD.R., VerdonR.Better adherence with once-daily antiretroviral regimens: a meta-analysis.Clin Infect Dis2009; 48: 484–488.
7.
SantosJ.R., Muñoz-MorenoJ.A., MoltóJ.Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ ritonavir: an exploratory study.PLoS ONE2013; 8: e70201.
8.
GutmannC., CusiniA., GunthardH.F.Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.AIDS2010; 24: 2347–2354.
9.
ImazA., CayuelaN., NiubóJ.Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression.AIDS Res Hum Retroviruses2014; 30: 984–987.
10.
EronJ.J., FeinbergJ., KesslerH.A.Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.J Infect Dis2004; 189: 265–272.
11.
González-GarcíaJ., CohenD., JohnsonM.Short communication: comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naive, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.AIDS Res Hum Retroviruses2010; 26: 841–845.
12.
CapparelliE.V., HollandD., OkamotoC.Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.AIDS2005; 19: 949–952.
13.
SolasC., LafeuilladeA., HalfonP., ChadapaudS., HittingerG., LacarelleB.Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.Antimicrob Agents Chemother2003; 47: 238–243.
14.
KnobelH., AlonsoJ., CasadoJ.L.Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.AIDS2002; 16: 605–613.
15.
Lopez-CortesL.F., Ruiz-ValderasR., Sánchez-RivasE.Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.Antimicrob Agents Chemother2013; 57: 3746–3751.
16.
KatnerH., KumarR., NylundC.Lopinavir/ritonavir once daily monotherapy pilot study. The MONDAKAL Study. IDWeek. 18 November 2012, San Diego, CA, USA. Poster 1353.
17.
CooperC., la PorteC., TossonianH.A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the, MONOCO study.HIV Clin Trials2012; 13: 179–188.
18.
ArribasJ.R., MontesM.L., PrakashM.: The MONET trial: correlation between hepatitis C co-infection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline. ISHEID 24 March 2010, Marseille, France. Abstract O-15.
19.
CalcagnoA., YilmazA., CusatocJ.Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.AIDS2012; 26: 1529–1533.
20.
Di YacovoM.S., MoltóJ., FerrerE.Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ ritonavir once daily in HIV-1 patients with plasma viral suppression.J Antimicrob Chemother2015; 70: 1513–1516.
